TIDMEDEN
RNS Number : 0514F
Eden Research plc
05 March 2020
5 March 2020
Eden Research plc
("Eden" or "Company)
Director/PDMR Shareholding
Eden Research plc (AIM: EDEN), the AIM quoted company that
develops and supplies breakthrough biopesticide products and
natural microencapsulation technologies to the global crop
protection, animal health and consumer products industries ,
announces that Lykele van der Broek, Non-Executive Chairman,
purchased a total of 571,000 ordinary shares of 1 pence each in the
capital of the Company ("Ordinary Shares") on 4 March 2020 at an
average price of 6.65 pence.
Following the transaction outlined above Mr van der Broek's
interest in the share capital of the Company is 929,500 Ordinary
Shares representing approximately 0.45 per cent. of the Company's
issued share capital.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provide further details of the
PDMR dealings set out above.
1 Details of the person discharging managerial responsibilities / person closely associated
a) Name Mr Lykele van der Broek
------------------------------------------------------------ -----------------------------------------------
2 Reason for the notification
-------------------------------------------------------------------------------------------------------------
a) Position/status Chairman
------------------------------------------------------------ -----------------------------------------------
b) Initial notification /Amendment Initial notification
------------------------------------------------------------ -----------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
-------------------------------------------------------------------------------------------------------------
a) Name Eden Research plc
------------------------------------------------------------ -----------------------------------------------
b) LEI 213800ZWTYTVQQSM3J85
------------------------------------------------------------ -----------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
-------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of instrument Ordinary shares of 1 pence each in the Company
Identification code GB0001646941
------------------------------------------------------------ -----------------------------------------------
b) Nature of the transaction Purchase of Ordinary Shares
------------------------------------------------------------ -----------------------------------------------
Price(s) Volume(s)
c) Price(s) and volume(s) 6.65 pence per 40,000 Ordinary
share Shares
6.65 pence per 100,000 Ordinary
share Shares
6.65 pence per 100,000 Ordinary
share Shares
6.65 pence per 150,000 Ordinary
share Shares
6.65 pence per 131,000 Ordinary
share Shares
6.65 pence per 50,000 Ordinary
share Shares
------------------
------------------------------------------------------------ -----------------------------------------------
d) Aggregated information
- Aggregated volume 571,000 Ordinary Shares
- Price 6.65 pence per share
------------------------------------------------------------ -----------------------------------------------
e) Date of the transaction 4/3/20
------------------------------------------------------------ -----------------------------------------------
f) Place of the transaction London Stock Exchange
------------------------------------------------------------ -----------------------------------------------
For further information contact:
Eden Research plc www.edenresearch.com
Sean Smith
Alex Abrey 01285 359 555
Cenkos Securities plc (Nominated advisor
and broker)
Giles Balleny / Cameron MacRitchie (corporate
finance)
Michael Johnson (sales) 020 7397 8900
Hawthorn Advisors
Lorna Cobbett 020 3745 4960
Jana Tsiligiannis eden@hawthornadvisors.com
Ed Curtis
Notes:
Eden Research is an AIM listed company that develops and
supplies breakthrough biopesticide products and natural
microencapsulation technologies to the global crop protection,
animal health and consumer products industries
Eden's Sustaine ä encapsulation technology harnesses the
biocidal efficacy of naturally occurring chemicals produced by
plants (terpenes) and can be used with both natural and synthetic
compounds to enhance their performance and ease-of-use.
Sustaine microcapsules are naturally derived, plastic-free,
biodegradable micro-spheres derived from yeast extract. They
produce stabilised aqueous suspensions which, are easy to mix and
apply, have phased release patterns, are safer for the environment
and the crops themselves.
The European Chemicals Agency (ECHA) has proposed an EU-wide
restriction on the placing on the market or use of
"intentionally-added" microplastic particles. The proposed
restriction includes the use of microplastics for agricultural and
horticultural purposes, including polymers utilized for
controlled-release fertilizers, encapsulated plant protection
products (PPPs), seed coatings, and biocides.
By 2025 in the EU, pesticides containing synthetic polymer
microplastics are likely to be banned and removed from the market.
The only acceptable alternative is the substitution with
biodegradable formulations. Reformulated products will need to be
evaluated and registered within the five-year transition
period.
Sustaine is one of the only viable, proven and immediately
registerable solutions to the microplastics problem in formulations
requiring encapsulation.
Historically, terpenes have had limited commercial use in the
agrochemical sector due to their volatility, phytotoxicity and poor
solubility. Sustaine provides a unique, environmentally friendly
solution to these problems and enables terpenes to be used as
effective, low-risk agrochemicals.
Eden is developing these technologies through innovative
research and a series of commercial production, marketing and
distribution partnerships.
The Company has a number of patents and a pipeline of products
at differing stages of development targeting specific areas of the
global agrochemicals industry. To date, the Company has invested in
the region of GBP14m in developing and protecting its intellectual
property and seeking regulatory approval for products that rely
upon the Company's technologies. Revenues earned by the Company
have been modest whilst the Company has concentrated on securing
patent protection for its intellectual property, gaining regulatory
approvals, identifying suitable industrial partners, and entering
into commercial agreements.
In May 2013, the three actives that comprise Eden's first
commercial product, Mevalone, were approved as new ingredients for
use in plant protection products by the European Commission ("EC").
This represented a major milestone in the commercialisation of
Eden's technology and is a significant accomplishment for any
company. To illustrate this point, one should note that in 2013,
Eden's approvals represented 3 of only 10 new active ingredients
approved by the EC.
Mevalone ä is a foliar fungicide which has been authorised for
sale in Kenya, Malta, Greece, Bulgaria,
Spain, Italy, France, Cyprus, Albania, Portugal and
Macedonia.
Cedroz ä is a nematicide which has been authorised for sale in
Malta, Belgium and Mexico.
Eden was admitted to trading on AIM on 11 May 2012 and trades
under the symbol EDEN.
For more information about Eden, please visit:
www.edenresearch.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHSSWFWLESSEID
(END) Dow Jones Newswires
March 05, 2020 02:00 ET (07:00 GMT)
Eden Research (LSE:EDEN)
Historical Stock Chart
From Apr 2024 to May 2024
Eden Research (LSE:EDEN)
Historical Stock Chart
From May 2023 to May 2024